Physician profile
Christopher W Chu
NPI 1326205873
$25,475.39
in general payments reported to CMS, 2019-2025
36 companies · $11K in 2025
The $11K reported for 2025 was more than what 95% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,082 · 2020: $1,294 · 2021: $1,564 · 2022: $2,469 · 2023: $2,921 · 2024: $5,631 · 2025: $11K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $10K · Consulting Fee: $7,300 · Travel and Lodging: $1,461 · Education: $301.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $10,005.58 |
| Consulting Fee | $7,300.00 |
| Travel and Lodging | $1,460.57 |
| Education | $300.70 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Mirum Pharmaceuticals, INC. | $7,328.83 | 2022-2025 | Livmarli |
| Actelion Pharmaceuticals US, INC. | $2,992.07 | 2019-2025 | Uptravi, Opsumit, Opsynvi |
| Astrazeneca Pharmaceuticals LP | $2,315.51 | 2019-2025 | Farxiga, Wainua, Lokelma |
| Bayer Healthcare Pharmaceuticals INC. | $2,302.71 | 2020-2025 | |
| Novartis Pharmaceuticals Corporation | $1,881.41 | 2019-2025 | |
| Edwards Lifesciences Corporation | $1,020.06 | 2020-2025 | Sapien 3 Ultra Resilia, Edwards Sapien 3 Transcatheter Heart Valve (Thv), Edwards Sapien 3 Ultra Transcatheter Heart Valve |
| Amgen INC. | $858.34 | 2019-2025 | Repatha, Repatha |
| Boehringer Ingelheim Pharmaceuticals, INC. | $845.22 | 2022-2025 | Jardiance |
| Boston Scientific Corporation | $842.64 | 2021-2025 | Avvigo Guidance System, Lux-Dx Insertable Cardiac Monitor, Emblem Mri S-Icd |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $753.50 | 2019-2025 | Lifevest |
| Pfizer INC. | $720.07 | 2020-2025 | |
| Abiomed | $460.44 | 2022-2025 | Impella |
| Janssen Pharmaceuticals, INC | $412.81 | 2019-2024 | Xarelto |
| Lexicon Pharmaceuticals, INC. | $382.73 | 2023-2024 | Inpefa |
| Esperion Therapeutics, INC. | $379.60 | 2021-2025 | Nexletol |
Show all 35 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Merck Sharp & Dohme LLC | $343.92 | 2022-2025 | Verquvo, Capvaxive |
| E.R. Squibb & Sons, L.L.C. | $295.64 | 2021-2025 | Camzyos, Eliquis |
| Mannkind Corporation | $176.73 | 2025 | |
| Sanofi-Aventis U.S. LLC | $158.08 | 2019-2022 | |
| Medtronic, INC. | $144.30 | 2021-2023 | Closurefast |
| Kiniksa Pharmaceuticals International, Plc | $144.19 | 2024 | Arcalyst |
| Kiniksa Pharmaceuticals, LTD. | $126.23 | 2021-2023 | Arcalyst |
| Novo Nordisk INC | $94.57 | 2024-2025 | Rybelsus, Ozempic, Wegovy |
| Scpharmaceuticals INC. | $91.59 | 2023-2025 | |
| Amarin Pharma, INC. | $87.08 | 2020-2021 | |
| Cvrx, INC. | $72.36 | 2022-2025 | Barostim Neo System |
| Elutia, INC. | $51.63 | 2021-2022 | |
| Ionis Pharmaceuticals, INC. | $32.86 | 2025 | Tryngolza |
| Kestra Medical Technology Services, INC. | $30.20 | 2022 | |
| Lilly USA, LLC | $27.15 | 2025 | Zepbound, Mounjaro |
| Bridgebio Pharma, INC. | $25.55 | 2025 | Attruby |
| Baxter Healthcare | $22.04 | 2023 | Hillrom - Cardiac Ambulatory Monitor |
| Glaxosmithkline, LLC. | $20.13 | 2025 | Shingrix, Arexvy |
| Covidien LP | $18.21 | 2019 | |
| Gilead Sciences, INC. | $16.99 | 2019 |
1 company reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Christopher Chu listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.